Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global antibody market size is estimated to be worth around 266.83 billion in 2024. The total market value of the antibodies sector is anticipated to increase at a CAGR of 8.1% from 2024 to 2033. Furthermore, it is anticipated that the market for antibodies will reach US$ 581.42 billion by 2034. The total market growth of the antibodies sector represented in absolute dollars is US$ 315 billion.
Report Attribute | Details |
---|---|
Antibody Market Size (2024) | US$ 266.83 billion |
Market Anticipated Forecast Value (2034) | US$ 581.42 billion |
Market Projected Growth Rate (2024 to 2034) | 8.1% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global antibody market was valued at US$ 131.47 billion in 2019. The market overview of antibody drugs progressed at an annual rate of 12.5% between 2019 and 2023. The overall market value was about US$ 236.86 billion by 2023.
Attributes | Details |
---|---|
Antibody Market Value (2019) | US$ 131.47 billion |
Market Revenue (2023) | US$ 236.86 billion |
Market Historical Growth Rate (CAGR 2019 to 2023) | 12.5% CAGR |
Research and Development Activities Impact Antibodies Sales Outlook
A surge in research and development activities among pharmaceutical market leaders to develop economical and effective antibodies is driving growth opportunities for diagnostic specialty antibody suppliers.
In February 2021, Abingdon Health collaborated with Abcam to explore opportunities for their service and portfolio expansion which includes Abcam's reagent portfolio and Abingdon Health's rapid test contract development and manufacturing services.
Rising cases of multiple sclerosis and Parkinson's disease among the older population is a key factor fueling the demand for antibodies. There is an urgency to develop personalized and cheap medicines, advanced therapeutics, advanced genetic engineering technology, and novel and effective treatments in middle-income countries.
In 2021, Berkeley Lights, a digital cell biology company, joined hands with Genovac, an antibody discovery company, to readily access the right antibodies in the shortest amount of time with the help of modern technology.
Increasing Production of Bio-similar Antibodies is Driving Demand
Biosimilar antibodies are experiencing heavy demand as they are inexpensive in comparison with human monoclonal antibodies, and they have very few side effects. In 2020, Johnson and Johnson reported US$ 3.75 Billion achieved through the sales of Remicade. According to Pfizer, Inflectra, the biosimilar competitor of Remicade, generated US$ 659 million in 2020.
USA Food and Drug Administration (FDA) approved a biosimilar of Remicade called Avsola in December 2019 and is now eligible for producing biologics products all over the world. Increasing demand for biosimilar antibodies in the treatment of rheumatoid arthritis, along with a high patient acceptance rate, is anticipated to boost the market growth for antibodies.
One of the leaders in prescription medicines, Pfizer, received EU approval for biosimilar antibody therapeutics Amsparity for Crohn’s disease, psoriasis, and psoriatic arthritis in February 2020. Elevated new drug approval rates and products in clinical trials in pharmaceutical companies are anticipated to further drive the market in the upcoming years.
The section below provides a market overview of antibody drugs and two other related industries. For instance, the significant rise of the global antibody fragment market has rendered it a distinct industry within the antibody testing market. On the other hand, emerging trends in antibody production are likely to further boost the target market in the coming days.
Antibody Market:
Attributes | Antibody Market |
---|---|
CAGR (2024 to 2034) | 8.1% |
Growth Factor | Strong investments in medical research and development are anticipated to fuel antibodies’ prospective growth. |
Market Opportunities | Low regulatory requirements make it a desirable option for antibody businesses and increase market potential exceptionally quickly. |
Key Trends | Growing Healthcare Industry Research Increases Demand for Antibody Production. |
Antibody Fragment Market:
Attributes | Antibody Fragment Market |
---|---|
CAGR (2024 to 2034) | 5.9% |
Growth Factor | Infectious and chronic diseases are becoming more common. |
Market Opportunities | The growing geriatric population in developing economies is anticipated to boost antibody fragments demand in the coming years. |
Key Trends | Increased industry-academia cooperation with the goal of addressing unmet medical needs worldwide. |
Antibody Production Market:
Attributes | Antibody Production Market |
---|---|
CAGR (2024 to 2034) | 13.5% |
Growth Factor | Increasing focus of biopharmaceutical and biotechnology companies on the production of antibody therapeutics. |
Market Opportunities | A focus on Research and Development is an essential strategy for driving the company's long-term growth. |
Key Trends | The production of therapeutic antibodies is increasing, which is anticipated to drive market growth during the forecast period. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below mentions the countries that are expected to witness higher growth opportunities in this market.
Regional Market Comparison | CAGR (2024 to 2034) |
---|---|
United States | 9.6% |
Germany | 9.4% |
United Kingdom | 10.1% |
India | 9.5% |
China | 6.5% |
The United States therapeutic antibodies market is poised to advance at a rate of 10.1% per year till 2034.
Consumption of antibody products in the United Kingdom is projected to rise at a rate of 10.1% during the forecast years.
The antibodies industry in China is projected to thrive at a CAGR of 5.8% through the projected years.
Sales of antibodies in Germany are anticipated to increase at a rate of 9.4% from 2024 to 2034.
Demand for antibodies in India is expected to rise at a rate of 9.5% per year between 2024 and 2034.
Based on product type, the monoclonal antibodies market segment is estimated to account for 95% of the market share in 2024.
Attributes | Details |
---|---|
Top Product Type or Segment | Monoclonal Antibodies |
Total Market Share in 2024 | 95% |
Based on disease indication, the use of antibodies for treating cancer is expected to account for 57% of the total sales in 2024.
Attributes | Details |
---|---|
Top Disease Indication Type or Segment | Cancer |
Total Market Share in 2024 | 57% |
Leading market players are working towards developing new antibodies to remain competitive in the present market. They are also researching to create long-acting antibody drugs to reduce healthcare costs and attract chronic patients.
In order to gain a competitive edge in the antibody testing market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic mergers and acquisitions for portfolio expansion are in the cards as well.
Future market players should concentrate on acquiring additional money through financing rounds to broaden their research and company scope. New businesses are looking into how to leverage cutting-edge technologies to streamline the creation of therapeutic antibodies, including nanobodies and monoclonal antibodies.
Recent Developments in the Global Antibody Market
On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment iptacopan, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that during 12 weeks of iptacopan monotherapy treatment, no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.
In August 2020, Johnson & Johnson entered into a final agreement to acquire Momenta Pharmaceuticals Inc. for around US$ 6.5 Billion. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.
The acquisition may allow the Janssen Pharmaceutical Companies of Johnson & Johnson to expand its product portfolio in immune-mediated diseases while driving growth opportunities through expansion into autoantibody-driven disease.
Leading pharmaceutical company Sanofi announced in March 2022 that it will collaborate with IGM Biosciences to research, produce, and market six novel immunoglobulin M antibody agonists. Sanofi has agreed to approximately US$ 6 billion in possible milestone payments through this agreement.
Attribute | Details |
---|---|
Estimated Market Size (2024) | US$ 266.83 billion |
Projected Market Size (2034) | US$ 581.42 billion |
Anticipated Growth Rate (2024 to 2034) | 8.1% |
Forecast Period | 2024 to 2034 |
Historical Data Available for | 2019 to 2023 |
Market Analysis | US$ million or billion for Value and Units for Volume |
Key Regions Covered | North America, Latin America, Europe, Middle East & Africa (MEA), East Asia, South Asia and Oceania |
Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, Spain, Italy, France, United Kingdom, Russia, China, India, Australia & New Zealand, GCC Countries, and South Africa |
Key Segments Covered | By Product Type, By Disease Indication, By End Use Verticals, and By Region |
Key Companies Profiled |
|
Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
Customization & Pricing | Available upon Request |
The global antibody market is estimated to be around US$ 266.83 billion in 2024.
The global antibody market is to grow at 8.1% during the forecast period.
The global antibody market is predicted to be valued at US$ 581.42 billion by 2034.
The global antibody market was valued at US$ 131.47 billion in 2019.
The United Kingdom to witness 10.1% CAGR in sales of antibodies through 2034.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2024 to 2034 5.3.1. Cardiovascular Diseases 5.3.2. CNS Disorders 5.3.3. Cancer 5.3.4. Autoimmune Disorders 5.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Disease Indication, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2024 to 2034 6.3.1. Monoclonal Antibodies 6.3.2. Polyclonal Antibodies 6.3.3. Antibody-Drug Complexes 6.4. Y-o-Y Growth Trend Analysis By Product Type, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Product Type, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2019 to 2023 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2024 to 2034 7.3.1. Hospitals 7.3.2. Long-Term Care Facilities 7.3.3. Research Institutes 7.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Disease Indication 9.2.3. By Product Type 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Disease Indication 9.3.3. By Product Type 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Disease Indication 10.2.3. By Product Type 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Disease Indication 10.3.3. By Product Type 10.3.4. By End User 10.4. Key Takeaways 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Disease Indication 11.2.3. By Product Type 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Disease Indication 11.3.3. By Product Type 11.3.4. By End User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Disease Indication 12.2.3. By Product Type 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Disease Indication 12.3.3. By Product Type 12.3.4. By End User 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Disease Indication 13.2.3. By Product Type 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Disease Indication 13.3.3. By Product Type 13.3.4. By End User 13.4. Key Takeaways 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Disease Indication 14.2.3. By Product Type 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Disease Indication 14.3.3. By Product Type 14.3.4. By End User 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Disease Indication 15.2.3. By Product Type 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Disease Indication 15.3.3. By Product Type 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Market Share Analysis, 2023 16.1.1.1. By Disease Indication 16.1.1.2. By Product Type 16.1.1.3. By End User 16.2. Canada 16.2.1. Market Share Analysis, 2023 16.2.1.1. By Disease Indication 16.2.1.2. By Product Type 16.2.1.3. By End User 16.3. Brazil 16.3.1. Market Share Analysis, 2023 16.3.1.1. By Disease Indication 16.3.1.2. By Product Type 16.3.1.3. By End User 16.4. Mexico 16.4.1. Market Share Analysis, 2023 16.4.1.1. By Disease Indication 16.4.1.2. By Product Type 16.4.1.3. By End User 16.5. Germany 16.5.1. Market Share Analysis, 2023 16.5.1.1. By Disease Indication 16.5.1.2. By Product Type 16.5.1.3. By End User 16.6. UK 16.6.1. Market Share Analysis, 2023 16.6.1.1. By Disease Indication 16.6.1.2. By Product Type 16.6.1.3. By End User 16.7. France 16.7.1. Market Share Analysis, 2023 16.7.1.1. By Disease Indication 16.7.1.2. By Product Type 16.7.1.3. By End User 16.8. Spain 16.8.1. Market Share Analysis, 2023 16.8.1.1. By Disease Indication 16.8.1.2. By Product Type 16.8.1.3. By End User 16.9. Italy 16.9.1. Market Share Analysis, 2023 16.9.1.1. By Disease Indication 16.9.1.2. By Product Type 16.9.1.3. By End User 16.10. Poland 16.10.1. Market Share Analysis, 2023 16.10.1.1. By Disease Indication 16.10.1.2. By Product Type 16.10.1.3. By End User 16.11. Russia 16.11.1. Market Share Analysis, 2023 16.11.1.1. By Disease Indication 16.11.1.2. By Product Type 16.11.1.3. By End User 16.12. Czech Republic 16.12.1. Market Share Analysis, 2023 16.12.1.1. By Disease Indication 16.12.1.2. By Product Type 16.12.1.3. By End User 16.13. Romania 16.13.1. Market Share Analysis, 2023 16.13.1.1. By Disease Indication 16.13.1.2. By Product Type 16.13.1.3. By End User 16.14. India 16.14.1. Market Share Analysis, 2023 16.14.1.1. By Disease Indication 16.14.1.2. By Product Type 16.14.1.3. By End User 16.15. Bangladesh 16.15.1. Market Share Analysis, 2023 16.15.1.1. By Disease Indication 16.15.1.2. By Product Type 16.15.1.3. By End User 16.16. Australia 16.16.1. Market Share Analysis, 2023 16.16.1.1. By Disease Indication 16.16.1.2. By Product Type 16.16.1.3. By End User 16.17. New Zealand 16.17.1. Market Share Analysis, 2023 16.17.1.1. By Disease Indication 16.17.1.2. By Product Type 16.17.1.3. By End User 16.18. China 16.18.1. Market Share Analysis, 2023 16.18.1.1. By Disease Indication 16.18.1.2. By Product Type 16.18.1.3. By End User 16.19. Japan 16.19.1. Market Share Analysis, 2023 16.19.1.1. By Disease Indication 16.19.1.2. By Product Type 16.19.1.3. By End User 16.20. South Korea 16.20.1. Market Share Analysis, 2023 16.20.1.1. By Disease Indication 16.20.1.2. By Product Type 16.20.1.3. By End User 16.21. GCC Countries 16.21.1. Market Share Analysis, 2023 16.21.1.1. By Disease Indication 16.21.1.2. By Product Type 16.21.1.3. By End User 16.22. South Africa 16.22.1. Market Share Analysis, 2023 16.22.1.1. By Disease Indication 16.22.1.2. By Product Type 16.22.1.3. By End User 16.23. Israel 16.23.1. Market Share Analysis, 2023 16.23.1.1. By Disease Indication 16.23.1.2. By Product Type 16.23.1.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Disease Indication 17.3.3. By Product Type 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Novartis AG 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. F. Hoffmann-La Roche Ltd. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Johnson & Johnson Services, Inc 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Takeda Pharmaceutical Company Limited 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Amgen Inc 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Biogen Inc 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Bristol-Myers Squibb Company 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. AbbVie Inc 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Sanofi 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Kyowa Kirin Co., Ltd 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. Iovance Biotherapeutics, Inc 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034 Table 2: Global Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034 Table 3: Global Market Value (US$ Million) Forecast by Product Type, 2019 to 2034 Table 4: Global Market Value (US$ Million) Forecast by End User, 2019 to 2034 Table 5: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 6: North America Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034 Table 7: North America Market Value (US$ Million) Forecast by Product Type, 2019 to 2034 Table 8: North America Market Value (US$ Million) Forecast by End User, 2019 to 2034 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 10: Latin America Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034 Table 11: Latin America Market Value (US$ Million) Forecast by Product Type, 2019 to 2034 Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2019 to 2034 Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 14: Western Europe Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034 Table 15: Western Europe Market Value (US$ Million) Forecast by Product Type, 2019 to 2034 Table 16: Western Europe Market Value (US$ Million) Forecast by End User, 2019 to 2034 Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 18: Eastern Europe Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034 Table 19: Eastern Europe Market Value (US$ Million) Forecast by Product Type, 2019 to 2034 Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User, 2019 to 2034 Table 21: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 22: South Asia and Pacific Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034 Table 23: South Asia and Pacific Market Value (US$ Million) Forecast by Product Type, 2019 to 2034 Table 24: South Asia and Pacific Market Value (US$ Million) Forecast by End User, 2019 to 2034 Table 25: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 26: East Asia Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034 Table 27: East Asia Market Value (US$ Million) Forecast by Product Type, 2019 to 2034 Table 28: East Asia Market Value (US$ Million) Forecast by End User, 2019 to 2034 Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Disease Indication, 2019 to 2034 Table 31: Middle East and Africa Market Value (US$ Million) Forecast by Product Type, 2019 to 2034 Table 32: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2019 to 2034
Figure 1: Global Market Value (US$ Million) by Disease Indication, 2024 to 2034 Figure 2: Global Market Value (US$ Million) by Product Type, 2024 to 2034 Figure 3: Global Market Value (US$ Million) by End User, 2024 to 2034 Figure 4: Global Market Value (US$ Million) by Region, 2024 to 2034 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034 Figure 8: Global Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034 Figure 9: Global Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034 Figure 10: Global Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034 Figure 11: Global Market Value (US$ Million) Analysis by Product Type, 2019 to 2034 Figure 12: Global Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034 Figure 13: Global Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034 Figure 14: Global Market Value (US$ Million) Analysis by End User, 2019 to 2034 Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2024 to 2034 Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034 Figure 17: Global Market Attractiveness by Disease Indication, 2024 to 2034 Figure 18: Global Market Attractiveness by Product Type, 2024 to 2034 Figure 19: Global Market Attractiveness by End User, 2024 to 2034 Figure 20: Global Market Attractiveness by Region, 2024 to 2034 Figure 21: North America Market Value (US$ Million) by Disease Indication, 2024 to 2034 Figure 22: North America Market Value (US$ Million) by Product Type, 2024 to 2034 Figure 23: North America Market Value (US$ Million) by End User, 2024 to 2034 Figure 24: North America Market Value (US$ Million) by Country, 2024 to 2034 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 28: North America Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034 Figure 29: North America Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034 Figure 30: North America Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034 Figure 31: North America Market Value (US$ Million) Analysis by Product Type, 2019 to 2034 Figure 32: North America Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034 Figure 33: North America Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034 Figure 34: North America Market Value (US$ Million) Analysis by End User, 2019 to 2034 Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2024 to 2034 Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034 Figure 37: North America Market Attractiveness by Disease Indication, 2024 to 2034 Figure 38: North America Market Attractiveness by Product Type, 2024 to 2034 Figure 39: North America Market Attractiveness by End User, 2024 to 2034 Figure 40: North America Market Attractiveness by Country, 2024 to 2034 Figure 41: Latin America Market Value (US$ Million) by Disease Indication, 2024 to 2034 Figure 42: Latin America Market Value (US$ Million) by Product Type, 2024 to 2034 Figure 43: Latin America Market Value (US$ Million) by End User, 2024 to 2034 Figure 44: Latin America Market Value (US$ Million) by Country, 2024 to 2034 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 48: Latin America Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034 Figure 51: Latin America Market Value (US$ Million) Analysis by Product Type, 2019 to 2034 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034 Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2019 to 2034 Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2024 to 2034 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034 Figure 57: Latin America Market Attractiveness by Disease Indication, 2024 to 2034 Figure 58: Latin America Market Attractiveness by Product Type, 2024 to 2034 Figure 59: Latin America Market Attractiveness by End User, 2024 to 2034 Figure 60: Latin America Market Attractiveness by Country, 2024 to 2034 Figure 61: Western Europe Market Value (US$ Million) by Disease Indication, 2024 to 2034 Figure 62: Western Europe Market Value (US$ Million) by Product Type, 2024 to 2034 Figure 63: Western Europe Market Value (US$ Million) by End User, 2024 to 2034 Figure 64: Western Europe Market Value (US$ Million) by Country, 2024 to 2034 Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 68: Western Europe Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034 Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034 Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034 Figure 71: Western Europe Market Value (US$ Million) Analysis by Product Type, 2019 to 2034 Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034 Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034 Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2019 to 2034 Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2024 to 2034 Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034 Figure 77: Western Europe Market Attractiveness by Disease Indication, 2024 to 2034 Figure 78: Western Europe Market Attractiveness by Product Type, 2024 to 2034 Figure 79: Western Europe Market Attractiveness by End User, 2024 to 2034 Figure 80: Western Europe Market Attractiveness by Country, 2024 to 2034 Figure 81: Eastern Europe Market Value (US$ Million) by Disease Indication, 2024 to 2034 Figure 82: Eastern Europe Market Value (US$ Million) by Product Type, 2024 to 2034 Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2024 to 2034 Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034 Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034 Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034 Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034 Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Product Type, 2019 to 2034 Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034 Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034 Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2019 to 2034 Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2024 to 2034 Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034 Figure 97: Eastern Europe Market Attractiveness by Disease Indication, 2024 to 2034 Figure 98: Eastern Europe Market Attractiveness by Product Type, 2024 to 2034 Figure 99: Eastern Europe Market Attractiveness by End User, 2024 to 2034 Figure 100: Eastern Europe Market Attractiveness by Country, 2024 to 2034 Figure 101: South Asia and Pacific Market Value (US$ Million) by Disease Indication, 2024 to 2034 Figure 102: South Asia and Pacific Market Value (US$ Million) by Product Type, 2024 to 2034 Figure 103: South Asia and Pacific Market Value (US$ Million) by End User, 2024 to 2034 Figure 104: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034 Figure 105: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 106: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 107: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 108: South Asia and Pacific Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034 Figure 109: South Asia and Pacific Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034 Figure 110: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034 Figure 111: South Asia and Pacific Market Value (US$ Million) Analysis by Product Type, 2019 to 2034 Figure 112: South Asia and Pacific Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034 Figure 113: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034 Figure 114: South Asia and Pacific Market Value (US$ Million) Analysis by End User, 2019 to 2034 Figure 115: South Asia and Pacific Market Value Share (%) and BPS Analysis by End User, 2024 to 2034 Figure 116: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034 Figure 117: South Asia and Pacific Market Attractiveness by Disease Indication, 2024 to 2034 Figure 118: South Asia and Pacific Market Attractiveness by Product Type, 2024 to 2034 Figure 119: South Asia and Pacific Market Attractiveness by End User, 2024 to 2034 Figure 120: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034 Figure 121: East Asia Market Value (US$ Million) by Disease Indication, 2024 to 2034 Figure 122: East Asia Market Value (US$ Million) by Product Type, 2024 to 2034 Figure 123: East Asia Market Value (US$ Million) by End User, 2024 to 2034 Figure 124: East Asia Market Value (US$ Million) by Country, 2024 to 2034 Figure 125: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 126: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 127: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 128: East Asia Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034 Figure 129: East Asia Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034 Figure 130: East Asia Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034 Figure 131: East Asia Market Value (US$ Million) Analysis by Product Type, 2019 to 2034 Figure 132: East Asia Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034 Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034 Figure 134: East Asia Market Value (US$ Million) Analysis by End User, 2019 to 2034 Figure 135: East Asia Market Value Share (%) and BPS Analysis by End User, 2024 to 2034 Figure 136: East Asia Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034 Figure 137: East Asia Market Attractiveness by Disease Indication, 2024 to 2034 Figure 138: East Asia Market Attractiveness by Product Type, 2024 to 2034 Figure 139: East Asia Market Attractiveness by End User, 2024 to 2034 Figure 140: East Asia Market Attractiveness by Country, 2024 to 2034 Figure 141: Middle East and Africa Market Value (US$ Million) by Disease Indication, 2024 to 2034 Figure 142: Middle East and Africa Market Value (US$ Million) by Product Type, 2024 to 2034 Figure 143: Middle East and Africa Market Value (US$ Million) by End User, 2024 to 2034 Figure 144: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034 Figure 145: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 146: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 147: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 148: Middle East and Africa Market Value (US$ Million) Analysis by Disease Indication, 2019 to 2034 Figure 149: Middle East and Africa Market Value Share (%) and BPS Analysis by Disease Indication, 2024 to 2034 Figure 150: Middle East and Africa Market Y-o-Y Growth (%) Projections by Disease Indication, 2024 to 2034 Figure 151: Middle East and Africa Market Value (US$ Million) Analysis by Product Type, 2019 to 2034 Figure 152: Middle East and Africa Market Value Share (%) and BPS Analysis by Product Type, 2024 to 2034 Figure 153: Middle East and Africa Market Y-o-Y Growth (%) Projections by Product Type, 2024 to 2034 Figure 154: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2019 to 2034 Figure 155: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2024 to 2034 Figure 156: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2024 to 2034 Figure 157: Middle East and Africa Market Attractiveness by Disease Indication, 2024 to 2034 Figure 158: Middle East and Africa Market Attractiveness by Product Type, 2024 to 2034 Figure 159: Middle East and Africa Market Attractiveness by End User, 2024 to 2034 Figure 160: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
Recommendations
Explore Healthcare Insights
View Reports